Tag:

Sanofi

Latest Headlines

Latest Headlines

Scientists call for development of quick Zika tests as epidemic rages on

As the Zika epidemic rages on, health experts are calling for the development of blood tests that can quickly and accurately pinpoint the virus and shed light on an associated condition in infants.

Sanofi commits to developing Zika vax while other big players will evaluate

Sanofi says it intends to apply its decades of vaccine development work and manufacturing expertise in dengue fever to try to create a vaccine for Zika virus, the mosquito-borne disease that the World Health Organization this week called a global health emergency.

Sanofi says job cuts in France should not involve plant closures

Sanofi is looking to trim 600 jobs in France as part of new CEO Olivier Brandicourt's plan to squeeze €1.5 billion in annual costs. The drugmaker says it does not plan on closing any plants in France as part of the process, but that does not mean that its production network in the home country will escape unscathed. Brandicourt has also said he will "reshape" the manufacturing network as part of his overall reorganization of the company.

Sanofi's Brandicourt mulls pulling the plug on Merck JV: Bloomberg

Back in 1994, Merck and Pasteur Merieux Connaught--now Sanofi Pasteur--teamed up on a joint venture to develop and market vaccines in Europe. Now, as Sanofi chief Olivier Brandicourt reorganizes the French pharma's operations in a cost-cutting bid, the 21-year-old partnership could be on the chopping block.

Sanofi launches Zika vaccine R&D effort

As the global alarm continues to sound about the Zika virus, Sanofi said on Tuesday that it's getting involved. In doing so, it became the first major pharmaceutical company to get involved in the Zika vaccine race, launching a program to develop a jab just after receiving the first regulatory approvals for its dengue shot.

UPDATED: Sanofi sharpens job-cutting ax with 500-plus in France

Sanofi is starting its latest round of job cuts with more than 500 in its home country. According to media reports, almost 300 open R&D jobs won't be filled, with another 250-plus cuts hitting Sanofi's commercial operations and corporate offices.

UPDATED: Sanofi chops into R&D operations in France in latest retrenchment

Following up on a plan to slim operations and cut $1.6 billion in costs, the new CEO at Paris-based Sanofi is taking an ax to 500 jobs, according to press reports.

Sanofi and Regeneron likely to cough up royalties to end Amgen's PCSK9 patent suit: Analyst

One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from Sanofi and Regeneron. They're apparently neck and neck with payers, and their script numbers aren't much different either, at least so far.

Zika outbreak triggers R&D attention from pharma, governments

As the Zika virus continues to grab headlines and its spread threatens, governments and industry are urgently committing resources and analyzing vaccine development options.

Sanofi's reportedly on the verge of 'sizable' job cuts as diabetes business sputters

French drugmaker Sanofi is soon to announce some "sizable" cuts to its payroll, according to Stat, part of new CEO Olivier Brandicourt's plot to engineer a turnaround.